Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications

S. L. Hoffman, C. N. Oster, C. V. Plowe, G. R. Woollett, John C Beier, J. D. Chulay, R. A. Wirtz, M. R. Hollingdale, M. Mugambi

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

The first human vaccines against the malaria parasite have been designed to elicit antibodies to the circumsporozoite protein of Plasmodium falciparum. However, it is not known whether any level of naturally acquired antibodies to the circumsporozoite protein can predict resistance to Plasmodium falciparum malaria. In this study, 83 adults in a malaria-endemic region of Kenya were tested for circumsporozoite antibodies and then treated for malaria. They were monitored for the development of new malaria infections for 98 days. Antibody levels, as determined by four assays in vitro, were indistinguishable between the 60 individuals who did and the 23 who did not develop parasitemia during follow-up, and there was no apparent relation between day of onset of parasitemia and level of antibodies to circumsporozoite protein. Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya.

Original languageEnglish
Pages (from-to)639-642
Number of pages4
JournalScience
Volume237
Issue number4815
DOIs
StatePublished - Oct 2 1987
Externally publishedYes

Fingerprint

Malaria Vaccines
Sporozoites
Antibodies
Malaria
Parasitemia
Kenya
Proteins
Falciparum Malaria
Plasmodium falciparum
Infection
Immunization
Parasites
Vaccines

ASJC Scopus subject areas

  • General

Cite this

Hoffman, S. L., Oster, C. N., Plowe, C. V., Woollett, G. R., Beier, J. C., Chulay, J. D., ... Mugambi, M. (1987). Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications. Science, 237(4815), 639-642. https://doi.org/10.1126/science.3299709

Naturally acquired antibodies to sporozoites do not prevent malaria : Vaccine development implications. / Hoffman, S. L.; Oster, C. N.; Plowe, C. V.; Woollett, G. R.; Beier, John C; Chulay, J. D.; Wirtz, R. A.; Hollingdale, M. R.; Mugambi, M.

In: Science, Vol. 237, No. 4815, 02.10.1987, p. 639-642.

Research output: Contribution to journalArticle

Hoffman, SL, Oster, CN, Plowe, CV, Woollett, GR, Beier, JC, Chulay, JD, Wirtz, RA, Hollingdale, MR & Mugambi, M 1987, 'Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications', Science, vol. 237, no. 4815, pp. 639-642. https://doi.org/10.1126/science.3299709
Hoffman, S. L. ; Oster, C. N. ; Plowe, C. V. ; Woollett, G. R. ; Beier, John C ; Chulay, J. D. ; Wirtz, R. A. ; Hollingdale, M. R. ; Mugambi, M. / Naturally acquired antibodies to sporozoites do not prevent malaria : Vaccine development implications. In: Science. 1987 ; Vol. 237, No. 4815. pp. 639-642.
@article{3ad6b6af8ccd42d1bc36f2e696148bf7,
title = "Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications",
abstract = "The first human vaccines against the malaria parasite have been designed to elicit antibodies to the circumsporozoite protein of Plasmodium falciparum. However, it is not known whether any level of naturally acquired antibodies to the circumsporozoite protein can predict resistance to Plasmodium falciparum malaria. In this study, 83 adults in a malaria-endemic region of Kenya were tested for circumsporozoite antibodies and then treated for malaria. They were monitored for the development of new malaria infections for 98 days. Antibody levels, as determined by four assays in vitro, were indistinguishable between the 60 individuals who did and the 23 who did not develop parasitemia during follow-up, and there was no apparent relation between day of onset of parasitemia and level of antibodies to circumsporozoite protein. Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya.",
author = "Hoffman, {S. L.} and Oster, {C. N.} and Plowe, {C. V.} and Woollett, {G. R.} and Beier, {John C} and Chulay, {J. D.} and Wirtz, {R. A.} and Hollingdale, {M. R.} and M. Mugambi",
year = "1987",
month = "10",
day = "2",
doi = "10.1126/science.3299709",
language = "English",
volume = "237",
pages = "639--642",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4815",

}

TY - JOUR

T1 - Naturally acquired antibodies to sporozoites do not prevent malaria

T2 - Vaccine development implications

AU - Hoffman, S. L.

AU - Oster, C. N.

AU - Plowe, C. V.

AU - Woollett, G. R.

AU - Beier, John C

AU - Chulay, J. D.

AU - Wirtz, R. A.

AU - Hollingdale, M. R.

AU - Mugambi, M.

PY - 1987/10/2

Y1 - 1987/10/2

N2 - The first human vaccines against the malaria parasite have been designed to elicit antibodies to the circumsporozoite protein of Plasmodium falciparum. However, it is not known whether any level of naturally acquired antibodies to the circumsporozoite protein can predict resistance to Plasmodium falciparum malaria. In this study, 83 adults in a malaria-endemic region of Kenya were tested for circumsporozoite antibodies and then treated for malaria. They were monitored for the development of new malaria infections for 98 days. Antibody levels, as determined by four assays in vitro, were indistinguishable between the 60 individuals who did and the 23 who did not develop parasitemia during follow-up, and there was no apparent relation between day of onset of parasitemia and level of antibodies to circumsporozoite protein. Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya.

AB - The first human vaccines against the malaria parasite have been designed to elicit antibodies to the circumsporozoite protein of Plasmodium falciparum. However, it is not known whether any level of naturally acquired antibodies to the circumsporozoite protein can predict resistance to Plasmodium falciparum malaria. In this study, 83 adults in a malaria-endemic region of Kenya were tested for circumsporozoite antibodies and then treated for malaria. They were monitored for the development of new malaria infections for 98 days. Antibody levels, as determined by four assays in vitro, were indistinguishable between the 60 individuals who did and the 23 who did not develop parasitemia during follow-up, and there was no apparent relation between day of onset of parasitemia and level of antibodies to circumsporozoite protein. Unless immunization with sporozoite vaccines induces antibodies that are quantitatively or qualitatively superior to the circumsporozoite antibodies in these adults, it is unlikely that such antibodies will prevent infection in areas with as intense malaria transmission as western Kenya.

UR - http://www.scopus.com/inward/record.url?scp=0023196018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023196018&partnerID=8YFLogxK

U2 - 10.1126/science.3299709

DO - 10.1126/science.3299709

M3 - Article

C2 - 3299709

AN - SCOPUS:0023196018

VL - 237

SP - 639

EP - 642

JO - Science

JF - Science

SN - 0036-8075

IS - 4815

ER -